You are here: Home » About Us » Company Overview
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company’s flagship product is the TactiCath®, the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Granted the CE mark in May 2009, it has undergone considerable pre-clinical and clinical validation, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Endosense’s target patient population is sizeable, as the TactiCath may be used to treat a range of cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting more than six million people worldwide. Currently, most AF patients are treated with pharmaceutical drugs that do not address the underlying cause and have side effects, with invasive ablation surgery as the primary treatment alternative. Endosense is focused on providing these patients with a minimally invasive treatment option that is both safe and effective.
Endosense’s exclusive TactiCath distributor for Europe, Latin America, Canada, the Middle East and Africa is BIOTRONIK. The TactiCath is currently not available in the United States.
Download Endosense Factsheet
68 Kb – PDF File